Elan’s Board Unanimously Rejects Royalty Pharma’s Revised Offer

Mani

Published onJune 10, 2013

Updated on May 13, 2021

Elan Corporation, plc (NYSE:ELN) today announced that its board of directors has rejected a revised bid from privately held investment firm Royalty Pharma.

Irish biotechnology firm Elan Corporation, plc (NYSE:ELN) said its board has rejected the offer from Royalty Pharma, through its subsidiary Echo Pharma Acquisition Ltd, to acquire all of the shares of Elan Corporation, plc (NYSE:ELN) for $13.00 plus up to an additional $2.50 per share in contingent voting rights (CVR).

What Elan Corporation Indicated:

The biotechnology firm Elan Corporation, plc (NYSE:ELN) indicated in a statement the gap between the underlying value of Elan Corporation...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article

Already a member? Log in here

Mani

Mani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations. He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications. His hobbies are tracking global financial developments and watching sports

Elan’s Board Unanimously Rejects Royalty Pharma’s Revised Offer

What Elan Corporation Indicated:

Login required to continue reading.

Get Your Business News